This is an old revision of the document!
Monika Naus
Dr. Monika Naus is a Canadian epidemiologist based in Vancouver, British Columbia.
Education
Naus obtained her medical training at the University of Alberta and her training in Public Health and Preventive Medicine at the University of Toronto.
She is a Fellow of the Royal College of Physicians of Canada and of the American College of Preventive Medicine.
Affiliations
Naus is active on the Canadian Immunization Committee, Canadian Immunization Registries and Coverage Network, Automated Identification of Vaccine Products Working Group, Canadian Immunization Research Network and other national and provincial committees.
Health Canada
Naus served as a federal field epidemiologist with the Laboratory Centre for Disease Control prior to starting her career in public health, with a focus on communicable disease prevention and control.
Public Health Agency of Canada
National Advisory Committee on Immunization
Naus is a liaison representative for the Canadian Immunization Committee on the National Advisory Committee on Immunization (NACI), where she was responsible for initially approving the COVID-19 vaccines in Canada.1) She previously served as Chair from 2003-2007 after being a member for eight years, and is a member of several NACI expert groups.
Ontario Ministry of Health and Long Term Care
Naus was the provincial epidemiologist in Ontario from 1997 to 2001, and a senior medical consultant in vaccine preventable diseases and TB control for the Ontario Ministry of Health and Long-Term Care from 1990 to 1997.
BC Centre for Disease Control
Naus is the Medical Director of the Communicable Diseases & Immunization Service at BC Centre for Disease Control (BCCDC).2) She began at the BCCDC in July 2001.
University of British Columbia
Naus is a professor in the University of British Columbia (UBC) School of Population & Public Health.3)
STRIVEBC
Naus is a member of the STRIVEBC (Sexually Transmitted Infections Vaccine) Consortium.4) The consortium is partnered with several World Health Organization-affiliated organizations, and those funded by the National Institutes of Health (NIH).5)
Research
Naus was part of a study funded by the Centres for Disease Control and Prevention studying H1N1 vaccines.6)
She has also received funding from the Michael Smith Foundation for Health Research and the Canadian Immunization Research Network (CIRN).7)
1)
National Advisory Committee on Immunization (NACI): Membership and representation. (2020, December 18). Wayback Machine; Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html
2)
, 3)
Monika Naus. BC Centre for Disease Control. Retrieved April 21, 2022, from http://www.bccdc.ca/our-research/people/monika-naus
4)
Consortium Members. STRIVEBC. Retrieved April 20, 2022, from https://archive.ph/EXe9G
5)
Affiliate Organizations. STRIVEBC. Retrieved April 20, 2022, from https://archive.ph/rYkGh
6)
Weibel, D., Sturkenboom, M., Black, S., de Ridder, M., Dodd, C., Bonhoeffer, J., Vanrolleghem, A., van der Maas, N., Lammers, G. J., Overeem, S., Gentile, A., Giglio, N., Castellano, V., Kwong, J. C., Murray, B. J., Cauch-Dudek, K., Juhasz, D., Campitelli, M., Datta, A. N., & Kallweit, U. (2018). Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment. Vaccine, 36(41), 6202–6211. https://doi.org/10.1016/j.vaccine.2018.08.008
7)
Donken, R., Dobson, S. R. M., Marty, K. D., Cook, D., Sauvageau, C., Gilca, V., Dionne, M., McNeil, S., Krajden, M., Money, D., Kellner, J., Scheifele, D. W., Kollmann, T., Bettinger, J. A., Liu, S., Singer, J., Naus, M., Sadarangani, M., & Ogilvie, G. S. (2019). Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial. Clinical Infectious Diseases, 71(4), 1022–1029. https://doi.org/10.1093/cid/ciz887